Carnosine prevents apoptosis of glomerular cells and podocyte loss in stz diabetic rats

Cellular Physiology and Biochemistry

Volumn 28, Issue 2, 2011, Pages 279-288

  Riedl, Eva ^a   Pfister, Frederick ^a   Braunagel, Margarita ^a   Brinkkötter, Paul ^a,b   Sternik, Paula ^a   Deinzer, Martina ^a   Bakker, Stephan J L ^c   Henning, Rob H ^c   Van Den Born, Jacob ^c   Krämer, Bernhard K ^a   Navis, Gerjan ^c   Hammes, Hans Peter ^a   Yard, Benito ^a   Koeppel, Hannes ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Carnosine; Diabetic nephropathy; Podocytes

Indexed keywords

APOPTOSIS INHIBITOR; CARNOSINE; CYTOCHROME C; HEXOSAMINE; N ACETYLGLUCOSAMINE; PROTEIN BAX; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LOSS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULUS; HYPERGLYCEMIA; MALE; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 80052085399     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000331740     Document Type: Article

References (52)

1. Forbes JM, Cooper ME, Oldfield MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003;14:S254-258. (Pubitemid 36903936)
2. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003;14:S241-245. (Pubitemid 36903933)
3. Schleicher ED, Weigert C: Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl 2000;77:S13-18.
4. Kang BP, Frencher S, Reddy V, Kessler A, Malhotra A, Meggs LG: High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. Am J Physiol Renal Physiol 2003;284:F455-466. (Pubitemid 36227906)
5. Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225-233. (Pubitemid 43343319)
6. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277:20309-20315. (Pubitemid 34967325)
7. Baba K, Minatoguchi S, Sano H, Kagawa T, Murata I, Takemura G, Hirano T, Ohashi H, Takemura M, Fujiwara T, Fujiwara H: Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble fas levels and pathological findings. Nephrology (Carlton) 2004;9:94-99. (Pubitemid 38530452)
8. Kumar D, Robertson S, Burns KD: Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 2004;259:67-70. (Pubitemid 38519217)
9. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP: Activated protein c protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007;13:1349-1358. (Pubitemid 350073598)
10. Jefferson JA, Shankland SJ, Pichler RH: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int 2008;74:22-36. (Pubitemid 351841893)
11. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type ii diabetes. J Clin Invest 1997;99:342-348. (Pubitemid 27053474)
12. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK: The podocyte and diabetes mellitus: Is the podocyte the key to the origins of diabetic nephropathy? Curr Opin Nephrol Hypertens 2008;17:32-36. (Pubitemid 350295194)
13. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626-1634. (Pubitemid 40770751)
14. Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in pima indians with type ii diabetes and microalbuminuria. Diabetologia 1999;42:1341-1344. (Pubitemid 29500971)
15. Freedman BI, Bowden DW, Sale MM, Langefeld CD, Rich SS: Genetic susceptibility contributes to renal and cardiovascular complications of type 2 diabetes mellitus. Hypertension 2006;48:8-13. (Pubitemid 44297513)
16. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-1165. (Pubitemid 19124296)
17. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, Rychlik I, Cerna M, Romzova M, de Heer E, Baelde H, Bakker SJ, Zirie M, Rondeau E, Mathieson P, Saleem MA, Meyer J, Koppel H, Sauerhoefer S, Bartram CR, Nawroth P, Hammes HP, Yard BA, Zschocke J, van der Woude FJ: Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the carnosinase gene cndp1. Diabetes 2005;54:2320-2327. (Pubitemid 41134258)
18. Riedl E, Koeppel H, Brinkkoetter P, Sternik P, Steinbeisser H, Sauerhoefer S, Janssen B, van der Woude FJ, Yard BA: A ctg polymorphism in the cndp1 gene determines the secretion of serum carnosinase in cos-7 transfected cells. Diabetes 2007;56:2410-2413. (Pubitemid 47358250)
19. Mooyaart AL, van Valkengoed IG, Shaw PK, Peters V, Baelde HJ, Rabelink TJ, Bruijn JA, Stronks K, de Heer E: Lower frequency of the 5/5 homozygous cndp1 genotype in south asian surinamese. Diabetes Res Clin Pract 2009;85:272-278.
20. Brownson C, Hipkiss AR: Carnosine reacts with a glycated protein. Free Radic Biol Med 2000;28:1564-1570. (Pubitemid 30604240)
21. Hipkiss AR, Chana H: Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 1998;248:28-32. (Pubitemid 28418181)
22. Hipkiss AR, Michaelis J, Syrris P: Nonenzymatic glycosylation of the dipeptide l-carnosine, a potential anti-proteincross-linking agent. FEBS Lett 1995;371:81-85.
23. Hipkiss AR, Preston JE, Himsworth DT, Worthington VC, Keown M, Michaelis J, Lawrence J, Mateen A, Allende L, Eagles PA, Abbott NJ: Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann N Y Acad Sci 1998;854:37-53. (Pubitemid 29022791)
24. Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC: Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005;513:145-150.
25. Fuji Y, Matsura T, Kai M, Kawasaki H, Yamada K: Protection by polaprezinc, an anti-ulcer drug, against indomethacininduced apoptosis in rat gastric mucosal cells. Jpn J Pharmacol 2000;84:63-70.
26. Matsuu-Matsuyama M, Shichijo K, Okaichi K, Nakayama T, Nakashima M, Uemura T, Niino D, Sekine I: Protection by polaprezinc against radiation-induced apoptosis in rat jejunal crypt cells. J Radiat Res (Tokyo) 2008;49:341-347. (Pubitemid 352030598)
27. Omatsu T, Naito Y, Handa O, Mizushima K, Hayashi N, Qin Y, Harusato A, Hirata I, Kishimoto E, Okada H, Uchiyama K, Ishikawa T, Takagi T, Yagi N, Kokura S, Ichikawa H, Yoshikawa T: Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacininduced small intestinal epithelial cell injury. J Gastroenterol 2010;45:692-702.
28. Odashima M, Otaka M, Jin M, Konishi N, Sato T, Kato S, Matsuhashi T, Nakamura C, Watanabe S: Induction of a 72-kda heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc l-carnosine. Dig Dis Sci 2002;47:2799-2804. (Pubitemid 35471625)
29. Baykara B, Tekmen I, Pekcetin C, Ulukus C, Tuncel P, Sagol O, Ormen M, Ozogul C: The protective effects of carnosine and melatonin in ischemia-reperfusion injury in the rat liver. Acta Histochem 2009;111:42-51.
30. Fouad AA, El-Rehany MA, Maghraby HK: The hepatoprotective effect of carnosine against ischemia/reperfusion liver injury in rats. Eur J Pharmacol 2007;572:61-68. (Pubitemid 47374680)
31. Fujii T, Takaoka M, Muraoka T, Kurata H, Tsuruoka N, Ono H, Kiso Y, Tanaka T, Matsumura Y: Preventive effect of lcarnosine on ischemia/reperfusion- induced acute renal failure in rats. Eur J Pharmacol 2003;474:261-267. (Pubitemid 37281459)
32. Fujii T, Takaoka M, Tsuruoka N, Kiso Y, Tanaka T, Matsumura Y: Dietary supplementation of l-carnosine prevents ischemia/reperfusion-induced renal injury in rats. Biol Pharm Bull 2005;28:361-363. (Pubitemid 40880025)
33. Kurata H, Fujii T, Tsutsui H, Katayama T, Ohkita M, Takaoka M, Tsuruoka N, Kiso Y, Ohno Y, Fujisawa Y, Shokoji T, Nishiyama A, Abe Y, Matsumura Y: Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats. J Pharmacol Exp Ther 2006;319:640-647.
34. Sauerhofer S, Yuan G, Braun GS, Deinzer M, Neumaier M, Gretz N, Floege J, Kriz W, van der Woude F, Moeller MJ: L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. Diabetes 2007;56:2425-2432. (Pubitemid 47523249)
35. Schonherr J: Analysis of products of animal origin in feeds by determination of carnosine and related dipeptides by highperformance liquid chromatography. J Agric Food Chem 2002;50:1945-1950. (Pubitemid 34259993)
36. Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, Schleicher ED: Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999;42:728-736. (Pubitemid 29265591)
37. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M: Overexpression of glyoxalase-i in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998;101:1142-1147. (Pubitemid 28125293)
38. Rashid I, van Reyk DM, Davies MJ: Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett 2007;581:1067-1070.
39. Calabrese V, Colombrita C, Guagliano E, Sapienza M, Ravagna A, Cardile V, Scapagnini G, Santoro AM, Mangiameli A, Butterfield DA, Giuffrida Stella AM, Rizzarelli E: Protective effect of carnosine during nitrosative stress in astroglial cell cultures. Neurochem Res 2005;30:797-807. (Pubitemid 41413937)
40. Kohen R, Yamamoto Y, Cundy KC, Ames BN: Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA 1988;85:3175-3179.
41. Seidler NW: Carnosine prevents the glycation-induced changes in electrophoretic mobility of aspartate aminotransferase. J Biochem Mol Toxicol 2000;14:215-220.
42. Yan H, Harding JJ: Carnosine protects against the inactivation of esterase induced by glycation and a steroid. Biochim Biophys Acta 2005;1741:120-126. (Pubitemid 40824997)
43. Aruoma OI, Laughton MJ, Halliwell B: Carnosine, homocarnosine and anserine: Could they act as antioxidants in vivo? Biochem J 1989;264:863-869. (Pubitemid 20023461)
44. Decker EA, Livisay SA, Zhou S: A reevaluation of the antioxidant activity of purified carnosine. Biochemistry (Mosc) 2000;65:766-770.
45. Davey CL: The significance of carnosine and anserine in striated skeletal muscle. Arch Biochem Biophys 1960;89:303-308.
46. Dunnett M, Harris RC: Influence of oral beta-alanine and l-histidine supplementation on the carnosine content of the gluteus medius. Equine Vet J Suppl 1999;30:499-504.
47. Johnson P, Aldstadt J: Effects of carnosine and anserine on muscle and non-muscle phosphorylases. Comp Biochem Physiol B 1984;78:331-333.
48. Yoshimura A, Uda S, Inui K, Nemoto T, Sugenoya Y, Sharif S, Yokota N, Watanabe S, Ideura T: Expression of bcl-and bax in glomerular disease. Nephrol Dial Transplant 1999;14 Suppl 1:55-57. (Pubitemid 29041840)
49. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 1998;54:687-697. (Pubitemid 28397387)
50. Mundel P, Shankland SJ: Podocyte biology and response to injury. J Am Soc Nephrol 2002;13:3005-3015. (Pubitemid 35386921)
51. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000;20:175-179. (Pubitemid 30445310)
52. Steffes MW, Schmidt D, McCrery R, Basgen JM: Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001;59:2104-2113. (Pubitemid 32467602)